OS Therapies agrees to acquire all immuno-oncology programs based in Listeria monotigenes and IP property from Ayal Pharmaceuticals, adding Pich cancer in phase 2 and Phaza 1 programs for prostration in Pi

admin1 day ago

0 0 Less than a minute